MedTrace Logo

Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)

NCT02742480 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2018-03-20

No results posted yet for this study

Summary

SEDMAN study is a prospective multicenter investigator initiated study (IIS). The main idea is to look by Genome Wide Association (arrays that determine more than 1 million polymorphisms) genetic risk factors associated with response to dabigatran. To conduct the study, the goal is to recruit 300 patients with ischemic stroke with cardioembolic etiology treated with dabigatran and 200 treated with Acenocoumarol to determine if genetic risk factors are associated with the occurrence of any bleeding or vascular event in a year follow-up.

Conditions

  • Cardioembolic Stroke

Interventions

DRUG

Dabigatran

DRUG

Acenocoumarol

Sponsors & Collaborators

  • Hospital Mutua de Terrassa

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-28
Primary Completion
2019-06-30
Completion
2019-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02742480 on ClinicalTrials.gov